Author: Shanghai Lishan Biopharmaceuticals Co., Ltd.

Posted Date:

February 7, 2026

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Shanghai Lishan Biopharmaceuticals Co., Ltd.

February 7, 2026